ACTRN12621001621808已完成1 期
A Randomized, Double-Blind and Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIR2446M after Oral Administrations in Healthy Volunteers
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- •1. Are capable of signing informed consent form (ICF) and complying with study procedures;
- •2. Male or female healthy participants between the ages of 18 and 55 years old, inclusive;
- •3. Women of childbearing potential (WOCBP) must be practicing a medically acceptable method of contraception with an annual failure rate of less than 1% during the study and 30 days after discontinuation of study treatment. Women are considered not childbearing potential if they are more than 1 year postmenopausal or surgically sterile (ie, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy tubal ligation).
- •4. All male patients with female partners of child-bearing potential must use two acceptable methods of contraception (one of which must be a barrier method), and must agree to abstain from sperm donation during and for 90 days after participation in the study.
- •5. Considered healthy by the Principal Investigator (PI) or delegate, based on a detailed medical history, full physical examination, clinical laboratory tests, 12-lead ECG and vital signs;
- •6. Nonsmoker/Social smoker, defined as not having smoked more than 2 nicotine/tobacco containing products per month in the last 3 months before screening. During the study, participant should be able to abstain from the use of nicotine/tobacco containing products;
- •7. Able to abstain from the consumption of alcohol and any alcohol-containing products from 48 hours before dosing to the end of the study;
- •8. Able to abstain from the consumption of coffee and any caffeine-containing products from 48 hours before dosing to the end of the study;
- •9. Body mass index (BMI) of 18 to 30 kg/m2 inclusive and body weight not less than 50 kg;
- •10. Willing and able to adhere to study restrictions and to be confined at the clinical research center.
排除标准
- •1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug hypersensitivity;
- •2. Clinically significant hematological findings at screening;
- •3. Abnormal findings indicating hepatic impairment, such as AST, ALT, or alkaline phosphatase greater than or equal to 1.5 times upper limit of normal (ULN), total bilirubin greater than or equal to 2.0 times ULN, albumin less than or equal to 3 g/dL, serum amylase or lipase greater than or 1.5 times ULN at screening;
- •4. Abnormal findings indicating renal impairment, such as creatinine greater than or equal to
- •1.5 times ULN, estimated creatinine clearance of 80 mL/minute or less calculated by the Cockcroft-Gault formula at screening;
- •5. Clinically significant ECG findings such as QTc value greater than or equal to 450 ms for male or greater than or equal to 470 ms for female at screening/day -1; 6. Participants with a mean systolic blood pressure of three measurements greater than 140 mmHg, or a mean diastolic blood pressure of three measurements greater than 90 mmHg at screening. Blood pressure will be measured at sitting position at screening; 7. Known or suspected malignancy, except adequately treated basal cell carcinoma;
- •8. Positive blood screen for human immunodeficiency virus (HIV), or hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) or nasopharynx swab test for SARS-CoV-2 (or any other test for COVID);
- •9. A history of seizure. However, a history of febrile seizure is allowed;
- •10. Plan to become pregnant during the study and within 30 days after the study;
- •11. A hospital admission or major surgery within 60 days prior to screening;
- •12. Receipt of any other investigational drug product within 3 months or 5 half-lives (whichever is longer) prior to dosing;
- •13. DSM-V substance use disorders and alcohol abuse within 12 months prior to screening;
- •14. A positive result for alcohol or drugs of abuse at screening or admission. Repeat test will be allowed if false positive is considered by the PI or designee;
- •15. An unwillingness or inability to comply with food and beverage restrictions during study participation, consumption of grapefruit or grapefruit juice within 14 days before dosing and until completed follow up assessments;
- •16. Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or blood products) or acute loss of blood during the 30 days prior to screening;
- •17. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John’s Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer or inhibitor) or 5 half-lives (whichever is longer) prior to dosing;
- •18. Use of vaccines (including COVID vaccine) within 7 days prior to dosing in SAD part and within 14 days prior to dosing in MAD part;
- •19. A history of suicide attempt in the past 12 months and/or seen by the Investigator as having a significant history of risk of suicide or homicide;
- •20. Participant has a known or suspected hypersensitivity toSIR2446M and any components of SIR2446M capsules or tablets;
- •21. Participant who has lactose intolerance history;
- •22. Participant has any other condition, which makes the participant unsuitable for study participation.
研究者
相似试验
已完成
1 期
A Randomized, Double-Blind and Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIR9900 after Oral Administrations in Healthy Adult VolunteersInflammatory diseases, particularly in central nervous systemDegenerative diseases, particularly in central nervous system.Inflammatory and Immune System - Other inflammatory or immune system disordersNeurological - Neurodegenerative diseasesACTRN12623000696695Sironax Aus Pty Ltd80
招募中
1 期
Phase 1 Study to Investigate SIR2501 in Healthy Adult ParticipantsACTRN12624000562572Sironax Australia Pty Ltd112
已完成
1 期
A Randomised, Double-Blind and Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIR9900 after Oral Administrations in Healthy Elderly Volunteers. (Multiple Ascending Dose (MAD), Part 2 Cohort 5).Inflammatory diseases, particularly in central nervous systemDegenerative diseases, particularly in central nervous systemInflammatory and Immune System - Other inflammatory or immune system disordersNeurological - Neurodegenerative diseasesACTRN12623000790640Sironax Aus Pty Ltd8
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis- Associated PaiModerate to Severe Endometriosis Associated PainMedDRA version: 19.0 Level: LLT Classification code 10014788 Term: Endometriosis related pain System Organ Class: 100000004872EUCTR2011-004295-11-GBAbbVie Deutschland GmbH & Co. KG815
进行中（未招募）
1 期
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis- Associated PaiModerate to Severe Endometriosis Associated PainMedDRA version: 16.0 Level: LLT Classification code 10014788 Term: Endometriosis related pain System Organ Class: 100000004872EUCTR2011-004295-11-ITAbbVie Deutschland GmbH & Co. KG815